Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 475

1.

Oral anticoagulants for stroke prevention in atrial fibrillation: current status, special situations, and unmet needs.

Verheugt FW, Granger CB.

Lancet. 2015 Mar 11. pii: S0140-6736(15)60245-8. doi: 10.1016/S0140-6736(15)60245-8. [Epub ahead of print] Review.

PMID:
25777666
2.

Association between edoxaban dose, concentration, anti-Factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial.

Ruff CT, Giugliano RP, Braunwald E, Morrow DA, Murphy SA, Kuder JF, Deenadayalu N, Jarolim P, Betcher J, Shi M, Brown K, Patel I, Mercuri M, Antman EM.

Lancet. 2015 Mar 10. pii: S0140-6736(14)61943-7. doi: 10.1016/S0140-6736(14)61943-7. [Epub ahead of print]

PMID:
25769361
3.

Cardiological aspects of stroke prevention.

Fisher M, McAllister M.

Circ J. 2015 Jan 23;79(2):271-7. doi: 10.1253/circj.CJ-14-1342. Epub 2015 Jan 7.

4.

Intracranial Hemorrhage Caused by Non-Vitamin K Antagonist Oral Anticoagulants (NOACs).

Saji N, Kimura K, Aoki J, Uemura J, Sakamoto Y.

Circ J. 2015 Feb 20. [Epub ahead of print]

5.

Impact of new oral anticoagulants on gastrointestinal bleeding in atrial fibrillation: A meta-analysis of interventional trials.

Loffredo L, Perri L, Violi F.

Dig Liver Dis. 2015 Feb 7. pii: S1590-8658(15)00189-9. doi: 10.1016/j.dld.2015.01.159. [Epub ahead of print]

PMID:
25732432
6.

Are the novel anticoagulants better than warfarin for patients with atrial fibrillation?

Hanley CM, Kowey PR.

J Thorac Dis. 2015 Feb;7(2):165-71. doi: 10.3978/j.issn.2072-1439.2015.01.23. Review.

7.

Efficacy and safety of oral anticoagulants versus aspirin for patients with atrial fibrillation: a meta-analysis.

Zhang JT, Chen KP, Zhang S.

Medicine (Baltimore). 2015 Jan;94(4):e409. doi: 10.1097/MD.0000000000000409.

PMID:
25634169
8.

Intratumoral Hemorrhage in a Patient with Malignant Meningioma under Anticoagulant Therapy.

Ito Y, Nakajima M, Watari M, Sakamoto T, Hashimoto Y, Tajiri S, Takada A, Ando Y.

J Stroke Cerebrovasc Dis. 2015 Jan 22. pii: S1052-3057(14)00566-7. doi: 10.1016/j.jstrokecerebrovasdis.2014.11.008. [Epub ahead of print]

PMID:
25620713
9.

Have a high index of suspicion for atrial fibrillation.

Leo M, Betts T.

Practitioner. 2014 Oct;258(1775):15-20, 2.

PMID:
25591283
10.

Trends in oral anticoagulant choice for acute stroke patients with nonvalvular atrial fibrillation in Japan: The SAMURAI-NVAF Study.

Toyoda K, Arihiro S, Todo K, Yamagami H, Kimura K, Furui E, Terasaki T, Shiokawa Y, Kamiyama K, Takizawa S, Okuda S, Okada Y, Kameda T, Nagakane Y, Hasegawa Y, Mochizuki H, Ito Y, Nakashima T, Takamatsu K, Nishiyama K, Kario K, Sato S, Koga M; SAMURAI Study Investigators.

Int J Stroke. 2015 Jan 12. doi: 10.1111/ijs.12452. [Epub ahead of print]

PMID:
25581108
11.

Meta-analysis on risk of bleeding with apixaban in patients with renal impairment.

Pathak R, Pandit A, Karmacharya P, Aryal MR, Ghimire S, Poudel DR, Shamoun FE.

Am J Cardiol. 2015 Feb 1;115(3):323-7. doi: 10.1016/j.amjcard.2014.10.042. Epub 2014 Nov 13.

PMID:
25527282
12.

Direct oral anticoagulants: new drugs and new concepts.

Levy JH, Spyropoulos AC, Samama CM, Douketis J.

JACC Cardiovasc Interv. 2014 Dec;7(12):1333-51. doi: 10.1016/j.jcin.2014.06.014.

PMID:
25523529
13.

Safety of novel oral anticoagulants compared with uninterrupted warfarin for catheter ablation of atrial fibrillation.

Armbruster HL, Lindsley JP, Moranville MP, Habibi M, Khurram IM, Spragg DD, Berger RD, Calkins H, Marine JE.

Ann Pharmacother. 2015 Mar;49(3):278-84. doi: 10.1177/1060028014563950. Epub 2014 Dec 16.

PMID:
25515868
14.

Stroke and systemic embolism prevention in patients with atrial fibrillation in Belgium: comparative cost effectiveness of new oral anticoagulants and warfarin.

Kongnakorn T, Lanitis T, Annemans L, Thijs V, Goethals M, Marbaix S, Wautrecht JC.

Clin Drug Investig. 2015 Feb;35(2):109-19. doi: 10.1007/s40261-014-0253-7.

PMID:
25511639
15.

Strategies for urgent reversal of target-specific oral anticoagulants.

Davis EM, Uhlmeyer EM, Schmidt DP, Schardt GL.

Hosp Pract (1995). 2014 Dec;42(5):108-25. doi: 10.3810/hp.2014.12.1164. Review.

PMID:
25485923
16.

Oral anticoagulation in atrial fibrillation.

Ansari JG, Garcha GS, Lakkis N.

Cardiovasc Hematol Agents Med Chem. 2014;12(1):34-41.

PMID:
25470152
17.

Novel oral anticoagulants in non-valvular atrial fibrillation.

da Silva RM.

Cardiovasc Hematol Agents Med Chem. 2014;12(1):3-8.

PMID:
25470147
18.

Non-vitamin K antagonist oral anticoagulants (NOACs) for stroke prevention in Asian patients with atrial fibrillation: time for a reappraisal.

Lip GY, Wang KL, Chiang CE.

Int J Cardiol. 2015 Feb 1;180:246-54. doi: 10.1016/j.ijcard.2014.11.182. Epub 2014 Nov 26.

PMID:
25463377
19.

Management of peri-operative anti-thrombotic therapy.

van Veen JJ, Makris M.

Anaesthesia. 2015 Jan;70 Suppl 1:58-67, e21-3. doi: 10.1111/anae.12900. Review.

PMID:
25440397
20.

Incidence, mortality, and risk factors for oral anticoagulant-associated intracranial hemorrhage in patients with atrial fibrillation.

Grysiewicz R, Gorelick PB.

J Stroke Cerebrovasc Dis. 2014 Nov-Dec;23(10):2479-88. doi: 10.1016/j.jstrokecerebrovasdis.2014.06.031. Epub 2014 Oct 29.

PMID:
25440361
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk